Ulka N. Vaishampayan

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg et al. · The Lancet · 2016 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +11

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · Journal of Clinical Oncology · 2014 · 1.1K citations · Full text

Medicine, Immunology, Oncology +17

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan et al. · The Lancet Oncology · 2013 · 1K citations · Full text

Medicine, Biostatistics, Oncology +14

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil et al. · Journal of Clinical Oncology · 2019 · 706 citations · Full text

Medicine, Oncology, Pharmacology +17

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

Maha Hussain, Catherine M. Tangen, Donna L. Berry et al. · New England Journal of Medicine · 2013 · 568 citations · Full text

Medicine, Oncology, Urology +14